Viracta

Viracta is a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. The lead product candidate is Nana-val, an all-oral combination therapy of their proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. (NASDAQ: VIRX)